Subscribe to RSS
DOI: 10.1055/a-2811-3019
Physiopathology of Exacerbation of Chronic Obstructive Pulmonary Disease
Authors
Abstract
Acute exacerbations of chronic obstructive pulmonary disease (ECOPD) represent crucial events in the natural history of the disease. These are mainly characterized by abrupt worsening of respiratory symptoms, that is, dyspnea, cough, and sputum production. Defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as acute symptom deterioration requiring additional therapy, ECOPD markedly worsens lung function and has strong clinical outcomes for any patient involved. Pathobiology is multidimensional, arising from inflammatory, mechanical, and cardiovascular perturbations that are linked to each other and are likely to generate a self-reinforcing cycle of respiratory derangement and/or failure. Indeed, lung inflammation and injuries intensify airflow limitation, which in turn promotes air trapping and dynamic hyperinflation, increases elastic loads, and predisposes to respiratory muscle dysfunction. The resulting alterations of the blood gases may lead to even severe respiratory system failure and to an increased risk of death.
Keywords
COPD - acute exacerbation - lung physiology - lung hyperinflation - lung compliance - airway resistanceDeclaration of GenAI Use
During the writing process of this paper, the authors used ChatGPT in order to improve language and readability. The authors reviewed and edited the text and take full responsibility for the content of the paper.
Contributors' Statement
R.T.: Conceptualization, writing–review and editing. S.M.: Writing–original draft, writing–review and editing. A.V.: Writing–review and editing. E.C.: Conceptualization, writing–review and editing.
‡ These authors contributed equally to this article.
Publication History
Received: 12 December 2025
Accepted: 10 February 2026
Accepted Manuscript online:
12 February 2026
Article published online:
24 February 2026
© 2026. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Global Initiative for Chronic Obstructive Lung Disease. 2026 GOLD Report and Pocket Guide. Global Strategy for Prevention, Diagnosis, and Management of COPD: 2026 Report.
- 2 Guo J, Chen Y, Zhang W, Tong S, Dong J. Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis. Int J Surg 2020; 78: 28-35
- 3 Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med 2019; 381 (13) 1257-1266
- 4 Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med 2013; 11: 181
- 5 Finney LJ, Fenwick P, Kemp SV. et al. Impaired antiviral immunity in frequent exacerbators of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2025; 328 (01) L120-L133
- 6 Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med 2020; 41 (03) 421-438
- 7 Riley CM, Sciurba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: A review. JAMA 2019; 321 (08) 786-797
- 8 Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005; 25 (04) 640-646
- 9 Wang Z, Locantore N, Haldar K. et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: A multicohort longitudinal analysis. Am J Respir Crit Care Med 2021; 203 (12) 1488-1502
- 10 Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016; 138 (01) 16-27
- 11 Liao S-X, Wang Y-W, Sun P-P, Xu Y, Wang T-H. Prospects of neutrophilic implications against pathobiology of chronic obstructive pulmonary disease: Pharmacological insights and technological advances. Int Immunopharmacol 2025; 144: 113634
- 12 Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J 2018; 52 (05) 52
- 13 Singh D, Agusti A, Martinez FJ. et al. Blood eosinophils and chronic obstructive pulmonary disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. Am J Respir Crit Care Med 2022; 206 (01) 17-24
- 14 David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax 2021; 76 (02) 188-195
- 15 Lee Y-L, Heriyanto DS, Yuliani FS. et al. Eosinophilic inflammation: a key player in COPD pathogenesis and progression. Ann Med 2024; 56 (01) 2408466
- 16 Sciurba FC, Criner GJ, Christenson SA. et al; MATINEE Study Investigators. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med 2025; 392 (17) 1710-1720
- 17 Mohamed MMG, Kamel G, Charbek E. Role of monoclonal antibodies in the management of eosinophilic chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. Ann Am Thorac Soc 2025; 22 (05) 768-775
- 18 Leung C, Park HY, Li X. et al. Transcriptomic profiling of the airway epithelium in COPD links airway eosinophilia to type 2 inflammation and corticosteroid response. Eur Respir J 2025; 65 (05) 2401875
- 19 Ma J, Rubin BK, Voynow JA. Mucins, mucus, and goblet cells. Chest 2018; 154 (01) 169-176
- 20 Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006; 86 (01) 245-278
- 21 Pincikova T, Merikallio H, Kotortsi I. et al. Expression levels of MUC5AC and MUC5B in airway goblet cells are associated with traits of COPD and progression of chronic airflow limitation. Int J Mol Sci 2024; 25 (24) 13653
- 22 Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010; 363 (23) 2233-2247
- 23 Widdicombe JH, Wine JJ. Airway gland structure and function. Physiol Rev 2015; 95 (04) 1241-1319
- 24 Boucher RC. Muco-obstructive lung diseases. N Engl J Med 2019; 380 (20) 1941-1953
- 25 Hill DB, Button B, Rubinstein M, Boucher RC. Physiology and pathophysiology of human airway mucus. Physiol Rev 2022; 102 (04) 1757-1836
- 26 Dunican EM, Elicker BM, Henry T. et al. Mucus plugs and emphysema in the pathophysiology of airflow obstruction and hypoxemia in smokers. Am J Respir Crit Care Med 2021; 203 (08) 957-968
- 27 Kim WD. Lung mucus: A clinician's view. Eur Respir J 1997; 10 (08) 1914-1917
- 28 Wan E, Yen A, Elalami R. et al. Airway mucus plugs on chest computed tomography are associated with exacerbations in COPD. Am J Respir Crit Care Med 2024; 211: 814-822
- 29 Li X, Feng S, Yang Y. et al. Association between airway mucus plugs and risk of moderate-to-severe exacerbations in patients with COPD: Results from a Chinese prospective cohort study. Chest 2025; 168 (03) 627-638
- 30 Koopman M, Posthuma R, Vanfleteren LEGW, Simons SO, Franssen FME. Lung hyperinflation as treatable trait in chronic obstructive pulmonary disease: A narrative review. Int J Chron Obstruct Pulmon Dis 2024; 19: 1561-1578
- 31 Gagnon P, Guenette JA, Langer D. et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 187-201
- 32 Gibson GJ. Pulmonary hyperinflation a clinical overview. Eur Respir J 1996; 9 (12) 2640-2649
- 33 Mergoni M, Rossi A. Physiopathology of acute respiratory failure in COPD and asthma. Minerva Anestesiol 2001; 67 (04) 198-205
- 34 Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006; 119 (10 suppl 1): 21-31
- 35 Puente-Maestu L, Stringer WW. Hyperinflation and its management in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1 (04) 381-400
- 36 West JB. Causes of and compensations for hypoxemia and hypercapnia. Compr Physiol 2011; 1 (03) 1541-1553
- 37 Csoma B, Vulpi MR, Dragonieri S. et al. Hypercapnia in COPD: Causes, consequences, and therapy. J Clin Med 2022; 11 (11) 3180
- 38 Barberà JA, Roca J, Ferrer A. et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997; 10 (06) 1285-1291
- 39 Petersson J, Glenny RW. Gas exchange and ventilation-perfusion relationships in the lung. Eur Respir J 2014; 44 (04) 1023-1041
- 40 Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004; 350 (26) 2689-2697
- 41 MacIntyre NR. Acute hypercapnic respiratory failure in COPD. Respir Care 2023; 68 (07) 973-982
- 42 Robinson TD, Freiberg DB, Regnis JA, Young IH. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161 (05) 1524-1529
- 43 Chabot F, Gomez E, Guillaumot A, Kheir A, Chaouat A. Acute exacerbations of chronic obstructive pulmonary disease. Presse Med 2009; 38 (03) 485-495
- 44 Klimathianaki M, Vaporidi K, Georgopoulos D. Respiratory muscle dysfunction in COPD: From muscles to cell. Curr Drug Targets 2011; 12 (04) 478-488
- 45 McKenzie DK, Butler JE, Gandevia SC. Respiratory muscle function and activation in chronic obstructive pulmonary disease. J Appl Physiol (1985) 2009; 107 (02) 621-629
- 46 Loring SH, Garcia-Jacques M, Malhotra A. Pulmonary characteristics in COPD and mechanisms of increased work of breathing. J Appl Physiol (1985) 2009; 107 (01) 309-314
- 47 Ottenheijm CAC, Heunks LMA, Dekhuijzen PNR. Diaphragm muscle fiber dysfunction in chronic obstructive pulmonary disease: Toward a pathophysiological concept. Am J Respir Crit Care Med 2007; 175 (12) 1233-1240
- 48 Alter A, Aboussouan LS, Mireles-Cabodevila E. Neuromuscular weakness in chronic obstructive pulmonary disease: Chest wall, diaphragm, and peripheral muscle contributions. Curr Opin Pulm Med 2017; 23 (02) 129-138
- 49 Gayan-Ramirez G, Decramer M. Mechanisms of striated muscle dysfunction during acute exacerbations of COPD. J Appl Physiol (1985) 2013; 114 (09) 1291-1299
- 50 Tobin MJ, Laghi F, Brochard L. Role of the respiratory muscles in acute respiratory failure of COPD: Lessons from weaning failure. J Appl Physiol (1985) 2009; 107 (03) 962-970
- 51 Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 2003; 290 (17) 2301-2312
- 52 Carteaux G, Parfait M, Combet M, Haudebourg AF, Tuffet S, Mekontso Dessap A. Patient-self inflicted lung injury: A practical review. J Clin Med 2021; 10 (12) 2738
- 53 Ranieri VM, Dambrosio M, Brienza N. Intrinsic PEEP and cardiopulmonary interaction in patients with COPD and acute ventilatory failure. Eur Respir J 1996; 9 (06) 1283-1292
- 54 Parrilla FJ, Morán I, Roche-Campo F, Mancebo J. Ventilatory strategies in obstructive lung disease. Semin Respir Crit Care Med 2014; 35 (04) 431-440
- 55 Grieco DL, Menga LS, Eleuteri D, Antonelli M. Patient self-inflicted lung injury: Implications for acute hypoxemic respiratory failure and ARDS patients on non-invasive support. Minerva Anestesiol 2019; 85 (09) 1014-1023
- 56 Greenblatt EE, Butler JP, Venegas JG, Winkler T. Pendelluft in the bronchial tree. J Appl Physiol (1985) 2014; 117 (09) 979-988
- 57 Pérez A, Erranz B, Reveco S. et al. CPAP improves regional lung strain rate and diaphragm velocity of relaxation in experimental self-inflicted lung injury. Crit Care 2025; 29 (01) 322
- 58 Marongiu I, Slobod D, Leali M, Spinelli E, Mauri T. Clinical and experimental evidence for patient self-inflicted lung injury (P-SILI) and bedside monitoring. J Clin Med 2024; 13 (14) 4018
- 59 Goligher EC, Jonkman AH, Dianti J. et al. Clinical strategies for implementing lung and diaphragm-protective ventilation: Avoiding insufficient and excessive effort. Intensive Care Med 2020; 46 (12) 2314-2326
- 60 Rastoder E, Sivapalan P, Hedsund C. et al. Pulmonary pressure increases during acute exacerbation in COPD and clinical outcome. Eur Respir J 2025; 66 (03) 2500169
- 61 Peinado VI, Santos S, Ramírez J, Roca J, Rodriguez-Roisin R, Barberà JA. Response to hypoxia of pulmonary arteries in chronic obstructive pulmonary disease: An in vitro study. Eur Respir J 2002; 20 (02) 332-338
- 62 MacDonald MI, Shafuddin E, King PT, Chang CL, Bardin PG, Hancox RJ. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med 2016; 4 (02) 138-148
- 63 Tannus-Silva DGS, Rabahi MF. State of the art review of the right ventricle in COPD patients: It is time to look closer. Lung 2017; 195 (01) 9-17
- 64 Celeski M, Segreti A, Polito D. et al. Traditional and advanced echocardiographic evaluation in chronic obstructive pulmonary disease: The forgotten relation. Am J Cardiol 2024; 217: 102-118
- 65 Fuhr DP, Brotto AR, Rowe BH, Bhutani M, Rosychuk RJ, Stickland MK. Examining changes in vascular function, arterial stiffness and systemic inflammation during hospitalization and recovery from an acute exacerbation of chronic obstructive pulmonary disease. Sci Rep 2023; 13 (01) 12245
- 66 Patel ARC, Kowlessar BS, Donaldson GC. et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188 (09) 1091-1099
- 67 Simons SO, Heptinstall AB, Marjenberg Z. et al. Temporal dynamics of cardiovascular risk in patients with chronic obstructive pulmonary disease during stable disease and exacerbations: Review of the mechanisms and implications. Int J Chron Obstruct Pulmon Dis 2024; 19: 2259-2271
- 68 Theodorakopoulou MP, Bakaloudi DR, Alexandrou ME. et al. Endothelial dysfunction during acute exacerbations of chronic obstructive pulmonary disease: A systematic review and meta-analysis. COPD 2021; 18 (02) 246-253
- 69 Bello-Perez M, García-Pachón E, Gonzalo-Jimenez N. et al. Gene expression profiles reveal distinct mechanisms driving chronic obstructive pulmonary disease exacerbations. Int J Mol Sci 2025; 26 (02) 627
- 70 Li Y, Mao X, Shi P. et al. Microbiome-host interactions in the pathogenesis of acute exacerbation of chronic obstructive pulmonary disease. Front Cell Infect Microbiol 2024; 14: 1386201
- 71 Lin Z, Liu S, Zhang K. et al. Molecular mechanisms and therapeutic targets of acute exacerbations of chronic obstructive pulmonary disease with Pseudomonas aeruginosa infection. Respir Res 2025; 26 (01) 115
- 72 Li CL, Liu SF. Exploring molecular mechanisms and biomarkers in COPD: An overview of current advancements and perspectives. Int J Mol Sci 2024; 25 (13) 7347
- 73 Mappin-Kasirer B, Pavord ID. Biological therapies in chronic obstructive pulmonary disease: New directions in personalised respiratory medicine. BioDrugs 2025; 39 (06) 827-839
- 74 Agusti A, Singh D, Faner R. Treatment of chronic obstructive pulmonary disease: Current pipeline and new opportunities. Nat Rev Drug Discov 2026; 25: 98-115
- 75 MacLeod M, Papi A, Contoli M. et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology 2021; 26 (06) 532-551
- 76 O'Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax 2006; 61 (04) 354-361
- 77 Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet 2022; 399 (10342): 2227-2242